List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3122478/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Elevated Lipoprotein(a) Level Influences Familial Hypercholesterolemia Diagnosis. Diseases (Basel,) Tj ETQq1 1 C	.784314 2.5	rgBT_/Overloc
2	Unsolved Issues of Atherosclerosis Prevention and of Adequate Lipid-lowering Therapy in Patients with Acute Ischemic Cerebrovascular Accident. Rational Pharmacotherapy in Cardiology, 2022, 17, 927-930.	0.8	0
3	Efficiency of high-intensity therapy with rosuvastatin for secondary prevention of cardiovascular complications in patients with a very high risk. Atherothrombosis, 2022, 11, 56-75.	0.3	0
4	Worldwide experience of homozygous familial hypercholesterolaemia: retrospective cohort study. Lancet, The, 2022, 399, 719-728.	13.7	69
5	Lipoprotein(a), Immune Cells and Cardiovascular Outcomes in Patients with Premature Coronary Heart Disease. Journal of Personalized Medicine, 2022, 12, 269.	2.5	13
6	Atorvastatin: old friend in the light of novel coronavirus infection's pandemia. Meditsinskiy Sovet, 2022, , 82-88.	0.5	0
7	Rhabdomyolysis is a rare complication of statin therapy. Case report and literature review. Kardiologicheskii Vestnik, 2022, 17, 84.	0.4	Ο
8	The relationship between the level of LÑ€(а) and the prevalence of atherosclerosis among young patients. Terapevticheskii Arkhiv, 2022, 94, 479-484.	0.8	1
9	A Clinical Case of a Homozygous Deletion in the APOA5 Gene with Severe Hypertriglyceridemia. Genes, 2022, 13, 1062.	2.4	3
10	Lipoprotein(a) concentration and the blood content of INFγ-producing T-helpers 17 (Th17/1) in males with premature coronary artery disease. Russian Journal of Cardiology, 2022, 27, 5046.	1.4	0
11	Association of various lipid parameters with premature coronary artery disease in men. Russian Journal of Cardiology, 2022, 27, 5058.	1.4	3
12	Prevalence of familial hypercholesterolemia and hyperlipoproteinemia(a) in patients with premature acute coronary syndrome. Russian Journal of Cardiology, 2022, 27, 5041.	1.4	2
13	News of the 90th Congress of the European Society of Atherosclerosis (EAS), Milan May 21-25, 2022. Russian Journal of Cardiology, 2022, 27, 5097.	1.4	0
14	News of the 90th Congress of the European Society of Atherosclerosis (EAS), Milan May 21-25, 2022. Russian Journal of Cardiology, 2022, 27, 5097.	1.4	0
15	The impact of type of dietary protein, animal versus vegetable, in modifying cardiometabolic risk factors: A position paper from the International Lipid Expert Panel (ILEP). Clinical Nutrition, 2021, 40, 255-276.	5.0	75
16	Lipoprotein(a), Immunity, and Inflammation in Polyvascular Atherosclerotic Disease. Journal of Cardiovascular Development and Disease, 2021, 8, 11.	1.6	12
17	Lipoprotein(a) and Cardiovascular Outcomes after Revascularization of Carotid and Lower Limbs Arteries. Biomolecules, 2021, 11, 257.	4.0	6
18	Existing problems and new possibilities in the treatment of dyslipidemia Joint Conclusion Based on the Results of the Expert Council. Rational Pharmacotherapy in Cardiology, 2021, 17, 169-172.	0.8	2

#	Article	IF	CITATIONS
19	Role of inflammation, autotaxin and lipoprotein (a) in degenerative aortic valve stenosis in patients with coronary artery disease. Cardiovascular Therapy and Prevention (Russian Federation), 2021, 20, 2598.	1.4	2
20	Lipoprotein(a) in an adult sample from the Russian population: distribution and association with atherosclerotic cardiovascular diseases. Archives of Medical Science, 2021, , .	0.9	4
21	EURASIAN ASSOCIATION OF CARDIOLOGY (EAC) GUIDELINES FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES IN PATIENTS WITH DIABETES AND PREDIABETES (2021). Eurasian Heart Journal, 2021, , 6-61.	0.8	9
22	The Association of Lipoprotein(a) and Circulating Monocyte Subsets with Severe Coronary Atherosclerosis. Journal of Cardiovascular Development and Disease, 2021, 8, 63.	1.6	11
23	Impact of nutraceuticals on markers of systemic inflammation: Potential relevance to cardiovascular diseases – A position paper from the International Lipid Expert Panel (ILEP). Progress in Cardiovascular Diseases, 2021, 67, 40-52.	3.1	39
24	Organization of lipid centers operation in the Russian Federation — new opportunities. Russian Journal of Cardiology, 2021, 26, 4489.	1.4	6
25	Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). Lancet, The, 2021, 398, 1713-1725.	13.7	142
26	Rehabilitation after COVID-19. Resolution of the International Expert Council of the Eurasian Association of Therapists and the Russian Society of Cardiology. Russian Journal of Cardiology, 2021, 26, 4694.	1.4	9
27	2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. European Heart Journal, 2020, 41, 111-188.	2.2	4,871
28	Effect of Evolocumab on Lipoprotein(a) and PCSK9 in Healthy Individuals with Elevated Lipoprotein(a) Level. Journal of Cardiovascular Development and Disease, 2020, 7, 45.	1.6	7
29	Therapeutic Apheresis for Management of Lp(a) Hyperlipoproteinemia. Current Atherosclerosis Reports, 2020, 22, 68.	4.8	11
30	An Exploratory Analysis of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition and Aortic Stenosis in the FOURIER Trial. JAMA Cardiology, 2020, 5, 709.	6.1	63
31	Verification of Underlying Genetic Cause in a Cohort of Russian Patients with Familial Hypercholesterolemia Using Targeted Next Generation Sequencing. Journal of Cardiovascular Development and Disease, 2020, 7, 16.	1.6	14
32	Carotid Intima-Media Thickness Progression as Surrogate Marker for Cardiovascular Risk. Circulation, 2020, 142, 621-642.	1.6	232
33	The Prospective Studies of Atherosclerosis (Proof-ATHERO) Consortium: Design and Rationale. Gerontology, 2020, 66, 447-459.	2.8	4
34	Lipoprotein(a) Lowering—From Lipoprotein Apheresis to Antisense Oligonucleotide Approach. Journal of Clinical Medicine, 2020, 9, 2103.	2.4	21
35	Statin therapy in athletes and patients performing regular intense exercise – Position paper from the International Lipid Expert Panel (ILEP). Pharmacological Research, 2020, 155, 104719.	7.1	17
36	Familial hypercholesterolemia: current status of the problem, treatment, and prevention. Cardiovascular Therapy and Prevention (Russian Federation), 2020, 19, 2532.	1.4	2

#	Article	IF	CITATIONS
07	EURASIAN ASSOCIATION OF CARDIOLOGY (EAC)/ RUSSIAN NATIONAL ATHEROSCLEROSIS SOCIETY (RNAS,) T		<u> </u>
37	TREATMENT OF ATHEROSCLEROSIS (2020). Eurasian Heart Journal, 2020, , 6-29.	0.8	28
38	Features of using of a fixed combination of rosuvastatin and ezetimibe for effective hypolipidemic therapy. Meditsinskiy Sovet, 2020, , 26-32.	0.5	3
39	Abstract 13769: Assessing the Risk for Cardiovascular Diseases According to Lipoprotein(a) Levels. Circulation, 2020, 142, .	1.6	0
40	The role of red yeast rice (RYR) supplementation in plasma cholesterol control: A review and expert opinion. Atherosclerosis Supplements, 2019, 39, e1-e8.	1.2	31
41	The Impact of the International Cooperation On Familial Hypercholesterolemia Screening and Treatment: Results from the ScreenPro FH Project. Current Atherosclerosis Reports, 2019, 21, 36.	4.8	13
42	The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: conceptual framework and therapeutic potential. Cardiovascular Diabetology, 2019, 18, 71.	6.8	104
43	Residual vascular risk in diabetes – Will the SPPARM alpha concept hold the key?. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2019, 13, 2723-2725.	3.6	4
44	Effect of the PCSK9 Inhibitor Evolocumab on Total Cardiovascular Events in Patients With Cardiovascular Disease. JAMA Cardiology, 2019, 4, 613.	6.1	66
45	Matrix Metalloproteinase 9 as a Predictor of Coronary Atherosclerotic Plaque Instability in Stable Coronary Heart Disease Patients with Elevated Lipoprotein(a) Levels. Biomolecules, 2019, 9, 129.	4.0	34
46	Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk. Circulation, 2019, 139, 1483-1492.	1.6	533
47	Register of patients with familial hypercholesterolemia and patients of very high cardiovascular risk with lipid-lowering therapy underperformance (RENESSANS). Russian Journal of Cardiology, 2019, , 7-13.	1.4	21
48	Correction of hypertriglyceridemia in order to reduce the residual risk in atherosclerosis-related diseases. Expert Council Opinion. Russian Journal of Cardiology, 2019, , 44-51.	1.4	10
49	Severe hyperlipoproteinemia(a) as a factor of rapidly progressive coronary artery disease in a young woman with heterozygous familial hypercholesterolemia. Russian Journal of Cardiology, 2019, , 72-73.	1.4	0
50	Fixeddose combination of rosuvastatin + ezetimibe: ease of use, safety and efficacy. Meditsinskiy Sovet, 2019, , 21-26.	0.5	2
51	Đ'Đ¾Đ·Đ¼Đ¾Đ¶Đ½Đ¾ÑŇ,ÑŒ Đ²Ñ‹ÑĐ²Đ»ĐµĐ½Đ,Ñ•ÑĐµĐ¼ĐµĐ¹Đ½D¾Đ¹ Đ³Đ,Đ;ĐµÑ€ÑĐ¾Đ»ĐµÑ	Ñ,ерÐ,й,	∕₂емÐĴ
52	Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). Atherosclerosis, 2018, 277, 234-255.	0.8	163
53	Apolipoprotein(a) phenotype determines the correlations of lipoprotein(a) and proprotein convertase subtilisin/kexin type 9 levels in patients with potential familial hypercholesterolemia. Atherosclerosis, 2018, 277, 477-482.	0.8	15
54	High Lipoprotein(a) Level is a Predictor of Peripheral Artery Disease Regardless of the Presence of Type 2 Diabetes. Atherosclerosis Supplements, 2018, 32, 42.	1.2	0

#	Article	IF	CITATIONS
55	The Role of Nutraceuticals in StatinÂIntolerant Patients. Journal of the American College of Cardiology, 2018, 72, 96-118.	2.8	216
56	ANTISENSE OLIGONUCLEOTIDES AND THERAPEUTICAL MONOCLONAL ANTIBODIES AS A BASEMENT FOR NOVEL BIOLOGICAL LIPIDLOWERING DRUGS. Russian Journal of Cardiology, 2018, , 99-109.	1.4	9
57	RAISED LEVEL OF LIPOPROTEIDE(A) AS A PREDICTOR OF CARDIOVASCULAR COMPLICATION POST REVASCULARIZATION OF THE LOWER EXTREMETIES ARTERIES. Russian Journal of Cardiology, 2018, , 7-12.	1.4	0
58	RAISED IgM AUTOANTIBODY TITER TO LIPOPROTEIDE(A) AS ANTIATHEROGENIC FACTOR IN SEVERE HYPERCHOLESTEROLEMIA PATIENTS. Russian Journal of Cardiology, 2018, , 13-20.	1.4	2
59	Inflammation markers in coronary heart disease patients with aortic valve stenosis. Russian Journal of Cardiology, 2018, , 17-22.	1.4	1
60	Lipid-lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel. Nutrition Reviews, 2017, 75, 731-767.	5.8	238
61	The presence of pathogenic mutations in patients with definite or probable diagnosis of familial hypercholesterolemia defined by targeted next generation sequencing. Atherosclerosis, 2017, 263, e231.	0.8	0
62	Frequency of familial hypercholesterolemia in patients with premature acute coronary syndrome. Atherosclerosis, 2017, 263, e230-e231.	0.8	1
63	Association of lipoprotein(a) level with short- and long-term outcomes after CABC: The role of lipoprotein apheresis. Atherosclerosis Supplements, 2017, 30, 187-192.	1.2	14
64	Lipid lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel. Archives of Medical Science, 2017, 5, 965-1005.	0.9	206
65	Lipoprotein(a) apheresis. Current Opinion in Lipidology, 2016, 27, 351-358.	2.7	17
66	Pooling and expanding registries of familial hypercholesterolaemia to assess gaps in care and improve disease management and outcomes: Rationale and design of the global EAS Familial Hypercholesterolaemia Studies Collaboration. Atherosclerosis Supplements, 2016, 22, 1-32.	1.2	90
67	Lipoprotein(a) level and apolipoprotein(a) phenotype as predictors of long-term cardiovascular outcomes after coronary artery bypass grafting. Atherosclerosis, 2014, 235, 477-482.	0.8	38
68	Effect of specific lipoprotein(a) apheresis on coronary atherosclerosis regression assessed by quantitative coronary angiography. Atherosclerosis Supplements, 2013, 14, 93-99.	1.2	102